Quality of life as a predictor for change in disability in MS

Neurology

Volumn 55, Issue 1, 2000, Pages 51-54

  Nortvedt, Monica W ^a   Riise, Trond ^a   Myhr, Kjell Morten ^b   Nyland, Harald I ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0034641272     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.1.51     Document Type: Article

References (27)

1. Ebers GC. Natural history of multiple sclerosis. In: Compston DAS, ed. MacAlpine's multiple sclerosis. London, UK: Churchill-Livingstone, 1998:191-221.
2. Agewall S, Wikstrand J, Fagerberg B. Stroke was predicted by dimensions of quality of life in treated hypertensive men. Stroke 1998;29:2329-2333.
3. Herlitz J, Wiklund I, Caidahl K, et al. The feeling of loneliness prior to coronary artery bypass grafting might be a predictor of short-and long-term postoperative mortality. Eur J Vasc Endovasc Surg 1998;16:120-125.
4. Møller L, Kristensen TS, Hollnagel H. Self rated health as a predictor of coronary heart disease in Copenhagen, Denmark. J Epidemiol Community Health 1996;50:423-428.
5. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-139.
6. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
7. Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Do the type I interferons improve the quality of life of MS-patients: results from a treatment trial on alfa-2a. Mult Scler 1999;5:317-322.
8. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999;52:57-62.
9. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999;52:50-56.
10. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1091-1103.
11. Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis. II. Quality of life. Can J Neurol Sci 1998; 25:31-38.
12. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997;48:74-80.
13. Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA. Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996;23:99-103.
14. Nyland H, Myhr KM, Lillås F, et al. Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway. Mult Scler 1996;1:372-375.
15. Myhr KM, Ruse T, Lillæs FEG, et al. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999;52:1049-1056.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
18. Radosevich DM, Wetzler H, Wilson SM. Health Status Questionnaire 2.0: scoring comparisons and reference data. Bloomington, MN: Health Outcome Institute, 1994.
19. Ware JE. SF-36 Health Survey manual & interpretation guide. Boston, MA: Nimrod Press, 1993.
20. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287.
21. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969.
22. Irwin M. Immune correlates of depression. Adv Exp Med Biol 1999;461:1-24.
23. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352(9139):1498-1504.
24. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186-204.
25. House JS, Robbins C, Metzner HL. The association of social relationships and activities with mortality: prospective evidence from the Tecumseh Community Health Study. Am J Epidemiol 1982;116:123-140.
26. Welin L, Tibblin G, Svardsudd K, et al. Prospective study of social influences on mortality. The study of men born in 1913 and 1923, Lancet 1985;1:915-918.
27. Ruberman W, Weinblatt E, Goldberg JD. Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984;311:552-559.